Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977780 · ClinicalTrials.gov registry record · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
A Phase 2 study of Glioblastoma, sponsored by Patrick Wen, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
- 12
- Study locations
NCT02977780 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Patrick Wen, MD. The registered enrollment target is 460 participants, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (330% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT02977780, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Patrick Wen, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Temozolomide
- DRUG Abemaciclib
- DRUG QBS10072S
- DRUG CC-115
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Rhode Island
- Lifespan / Rhode Island Hospital - Providence
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02977780
The ClinicalTrials.gov registry entry for NCT02977780 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 107-participant average among 199 other Glioblastoma trials with a reported enrollment target (330% higher). The listed sponsor is Patrick Wen, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Neratinib is the first listed.
NCT02977780 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT02977780 about?
NCT02977780 is a clinical study titled "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)". This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currentl...
What is the current status of trial NCT02977780?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2017-02-09. Estimated completion is 2028-04-30.
What conditions does trial NCT02977780 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02977780?
The interventions under investigation include: Neratinib (DRUG), Temozolomide (DRUG), Abemaciclib (DRUG), QBS10072S (DRUG), CC-115 (DRUG).
Who is sponsoring clinical trial NCT02977780?
This trial is sponsored by Patrick Wen, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977780 being conducted?
This trial has 12 study locations across Alabama, Massachusetts, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.